3.Efficacy of antioxidants in treatment of nonalcoholic fatty liver: a systematic review.
Mingxi ZENG ; Yiping WANG ; Liping WU
Journal of Southern Medical University 2012;32(5):695-702
OBJECTIVETo evaluate the efficacy of antioxidants in the treatment of non-alcoholic fatty liver.
METHODSThe Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE or PUBMED (1978-2011), EMBASE (1978-2011), ISI, OVID Database (1978-2011), CNKI Net and WANFANG database (1978-2011) were searched for relevant randomized controlled trials, with also manual search of the bibliographies of the retrieved articles. The data were synthesized to assess the histological response of the patients (hepatic steatosis, inflammation and fibrosis) and hepatic biochemical changes after the treatments (alanine aminotransferase responses).
RESULTSFourteen trials involving 1284 patients were included in the Meta-analysis. The quality of the trials was inconsistent. The data were extracted for meta-analysis or descriptive analysis, which did not yield sufficient evidence that antioxidants could improve hepatic steatosis, inflammation, fibrosis or alanine aminotransferase responses.
CONCLUSIONSThe current data do not support a positive therapeutic effect of antioxidants on nonalcoholic fatty liver, and antioxidants are therefore not recommended in the clinical treatment of the condition.
Antioxidants ; therapeutic use ; Fatty Liver ; drug therapy ; Humans ; Non-alcoholic Fatty Liver Disease ; Randomized Controlled Trials as Topic ; Treatment Outcome
4.Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach.
Liang DAI ; Jingjuan XU ; Baocheng LIU ; Yanqi DANG ; Ruirui WANG ; Lijie ZHUANG ; Dong LI ; Lulu JIAO ; Jianying WANG ; Lei ZHANG ; Linda L D ZHONG ; Wenjun ZHOU ; Guang JI
Frontiers of Medicine 2022;16(5):745-759
Lingguizhugan Decoction (LGZG) has been investigated in basic studies, with satisfactory effects on insulin resistance in non-alcoholic fatty liver disease (NAFLD). This translational approach aimed to explore the effect and underlying mechanism of LGZG in clinical setting. A randomized, double-blinded, placebo-controlled trial was performed. A total of 243 eligible participants with NAFLD were equally allocated to receive LGZG (two groups: standard dose and low dose) or placebo for 12 weeks on the basis of lifestyle modifications. The primary efficacy variable was homeostasis model assessment of insulin resistance (HOMA-IR). Analyses were performed in two populations in accordance with body mass index (BMI; overweight/obese, BMI ⩾ 24 kg/m2; lean, BMI < 24 kg/m2). For overweight/obese participants, low-dose LGZG significantly decreased their HOMA-IR level compared with placebo (-0.19 (1.47) versus 0.08 (1.99), P = 0.038). For lean subjects, neither dose of LGZG showed a superior effect compared with placebo. Methylated DNA immunoprecipitation sequencing and real-time qPCR found that the DNA N6-methyladenine modification levels of protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and autophagy related 3 (ATG3) significantly increased after LGZG intervention in overweight/obese population. Low-dose LGZG effectively improved insulin resistance in overweight/obese subjects with NAFLD. The underlying mechanism may be related to the regulation of DNA N6-methyladenine modification of PPP1R3A and ATG3. Lean subjects may not be a targeted population for LGZG.
Humans
;
Non-alcoholic Fatty Liver Disease/drug therapy*
;
Overweight/drug therapy*
;
Insulin Resistance
;
Obesity/drug therapy*
;
China
;
DNA/therapeutic use*
8.Treatment of nonalcoholic steatohepatitis by Jianpi Shugan Recipe: a multi-center, randomized, controlled clinical trial.
Jun-Xiang LI ; Yun-Liang WANG ; Min LIU ; Shao-Neng LIU ; Chun-Jun XU ; Jing ZHAO ; Rui SHI ; Dong-Mei SU ; Li ZHUGE ; Xi CHEN ; Yi-Qun YU ; Li LI ; Chun-E XIE ; Li-Ming HU ; Chang ZHANG
Chinese Journal of Integrated Traditional and Western Medicine 2014;34(1):15-19
OBJECTIVETo evaluate the efficacy and safety of Chinese medicine (CM) intervention in the treatment of nonalcoholic steatohepatitis (NASH) from liver enzyme (ALT), imaging (the liver/spleen CT ratio) and syndrome scores, and to establish standard methods for diagnosis and therapeutic efficacy evaluation with characteristics of CM.
METHODSA multi-center, stratified randomized, parallel controlled, blindness-method evaluated, superiority trial was performed. Totally 204 patients were randomly allocated into two groups, 102 patients in the experimental group (treated with CM) and 102 patients in the control group [treated with Western medicine (WM)]. The alanine aminotransferase (ALT), liver/spleen CT ratio, and clinical symptoms were observed in both groups.
RESULTSOf the randomly allocated 204 cases from 4 hospitals, 3 patients were rejected, and 25 were lost. Totally 176 cases con- formed to the plan with complete follow-ups. After 3 months of treatment, syndrome scores and the improvement of partial clinical symptoms (fatigue and sallow complexion) were superior in the experimental group to those in the control group (P < 0.05). After 3 months of follow-up, the syndrome scores and improvement of partial clinical symptoms (fatigue and sallow complexion) were superior in the experimental group to those in the control group (P < 0.05). There was no statistical difference in improving liver enzymes or the liver/spleen CT ratio between the two groups (P > 0.05). There were 4 adverse reactions/adverse events in the two groups in the process of treatment, mainly covering drug-induced liver injury, diarrhea, and epigastric distension. Adverse reactions had nothing to do with CM treatment.
CONCLUSIONSJianpi Shugan Recipe had obvious efficacy in treatment of NASH. It could remove the liver fat and play a role in anti-inflammation and liver protection. It also could improve the indices of liver enzymes and the liver/spleen CT ratio effectively, which was superior to Polyene Phosphatidylcholine Capsule (PPC) in improving clinical symptoms, especially for such symptoms as fatigue and sallow complexion.
Adult ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; drug therapy ; Phytotherapy
9.Clinical efficacy of compound glycyrrhizin tablets in the treatment of children with nonalcoholic fatty liver disease.
Yu-Wen LI ; Yu-Hua HU ; Tian-Tian ZHU ; An-Zhen CHU ; Chuan-Long ZHU
Chinese Journal of Contemporary Pediatrics 2017;19(5):505-509
Department of Pediatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. zhuchuanlong@jsph.org.cn.
Adolescent
;
Child
;
Female
;
Glycyrrhizic Acid
;
therapeutic use
;
Humans
;
Male
;
Non-alcoholic Fatty Liver Disease
;
drug therapy
;
Tablets
10.Clinical study of Qinggan Huatan Huoxue Recipe on the treatment of non-alcoholic steatohepatitis.
Qiang PEI ; Xiao-Su WANG ; Xian-Bo WANG
Chinese Journal of Integrated Traditional and Western Medicine 2012;32(1):29-31
OBJECTIVETo observe the therapeutic effects of Qinggan Huatan Huoxue Recipe (QHHR) on patients with non-alcoholic steatohepatitis (NASH).
METHODSOne hundred and fifty NASH patients were randomly assigned to the treatment group (78 cases) and the control group (72 cases). QHHR was given to patients in the treatment groups, while Danning Tablet was given to those in the control group. The therapeutic course for all was three months. Before and after treatment changes of clinical symptoms and physical signs, liver imageology, liver functions, blood lipids, and insulin resistance index (IRI) were observed.
RESULTSCompared with before treatment, obvious improvement of clinical symptoms, weight, body mass index (BMI), liver functions, blood lipids, and integral of liver ultrasound B was obtained in the two groups (P < 0.05). The IRI of the treatment group was significantly reduced after treatment (P < 0.05). Better effects were obtained in lowering the body weight, BMI, alanine aminotransferase (ALT), gamma glutamyltransferase (gamma-GT), triglyceride (TG), total cholesterol (TC), integral of liver ultrasound B, and the total effective rate (P < 0.05).
CONCLUSIONSQHHR had definite effects on NASH. Its therapeutic effects were better than Danning Tablet.
Adolescent ; Adult ; Aged ; Drugs, Chinese Herbal ; therapeutic use ; Fatty Liver ; drug therapy ; Female ; Humans ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Phytotherapy ; Young Adult